The 2022 Cochrane Review Group Impact Factor for the Cochrane Skin Group increased to 9.258.
This therefore means that a review published by the Skin Group Skin Group in 2020 and 2021 was cited, on average, 9.2 times in 2022. This represents an increase on the 2021 Impact Factor, which was 7.400. Thank you to all who have contributed!
Congratulations to the authors of the top ten highest-cited reviews for the Skin Group contributing to the 2022 Impact Factor:
|Times Cited||Title||CD Number||Publication Date|
|44||Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis||CD011535.pub3||Jan-20|
|13||Oral H1 antihistamines as 'add-on' therapy to tropical treatment for eczema||CD012167.pub2||Jan-19|
|13||Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma||CD012806.pub2||Jul-19|
|12||Interventions to reduce Staphylococcus aureus in the management of eczema||CD003871.pub2||Oct-19|
|11||Topical and deviced-based treatments for fungal infections of the toenails||CD012093.pub2||Jan-20|
|10||Screening fro reducing morbidity and mortality in malignant melanoma||CD012352.pub2||Jun-19|
|8||Interventions fro chronic palmoplantar pustulosis||CD011628.pub2||Jan-20|
|7||Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care sttings||CD011377.pub2||Jan-20|
|7||Antistreptococcal interventions for guttate and chronic plaque psoriasis||CD011571.pub2||Mar-19|
|7||Interventions for chronic pruritus of unknown origin||CD013128.pub2||Jan-20|